Tsukagoshi S, Ohta J, Taguchi T
Cancer Chemotherapy Center, Japanese Foundation for Cancer Research.
Gan To Kagaku Ryoho. 1993 Dec;20(15):2276-81.
This paper described an outline of clinically applications of 5-HT3 receptor antagonists, mainly on ondansetron, which control nausea and vomiting associated with cancer chemotherapy. Clinically, 5-HT3 receptor antagonists demonstrated significantly superior antiemetic effects to metoclopramide which has been prescribed for relatively long time. The response rates for granisetron and those for ondansetron were different due to the different categorical scales. However, when the same scale was applied, similar efficacies have been observed. Introduction of the tablet form may well broaden the clinical applications. Considering the highly evaluated safety, 5-HT3 receptor antagonists, from the viewpoints of clinical usefulness and safety, seems to be useful drugs for controlling nausea and vomiting associated with cancer chemotherapy.
本文描述了5-羟色胺3(5-HT3)受体拮抗剂的临床应用概况,主要是关于控制癌症化疗相关恶心和呕吐的昂丹司琼。临床上,5-HT3受体拮抗剂显示出比已使用较长时间的甲氧氯普胺显著优越的止吐效果。由于分类量表不同,格拉司琼和昂丹司琼的有效率有所不同。然而,当应用相同量表时,观察到了相似的疗效。片剂形式的引入很可能会拓宽临床应用。考虑到高度评价的安全性,从临床实用性和安全性的角度来看,5-HT3受体拮抗剂似乎是控制癌症化疗相关恶心和呕吐的有用药物。